|
In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells
|
Homo sapiens
|
8.0
nM
|
|
|
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures
|
Anas sp.
|
0.01
ug.mL-1
|
|
|
In vitro antiviral activity against Hepatitis B virus in primary duck hepatocyte (DHBV) cultures and expressed as percent inhibition of viral DNA at 10 ug/mL
|
Anas sp.
|
96.0
%
|
|
|
Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes
|
Duck hepatitis B virus
|
96.0
%
|
|
|
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls.
|
Duck hepatitis B virus
|
0.01
ug.mL-1
|
|
|
Compound was tested for its antiviral activity against hepatitis B virus(DHBV) in duck fetal hepatocytes culture
|
Anas sp.
|
100.0
nM
|
|
|
Antiviral activity against Hepatitis B virus (HBV) in 2.2.15 cells
|
Hepatitis B virus
|
8.0
nM
|
|
|
In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV
|
Homo sapiens
|
400.0
nM
|
|
|
Antiviral activity against Immunodeficiency virus type-1 (HIV-1) in peripheral blood mononuclear cells
|
Human immunodeficiency virus 1
|
70.0
nM
|
|
|
Percent inhibition for its anti-HBV activity in infected HepG2(2.2.15) cells at concentration of 1 uM
|
Homo sapiens
|
87.0
%
|
|
|
Tested for the effective concentration required to inhibit HBV in HepG2.2.15 human liver cells
|
Homo sapiens
|
200.0
nM
|
|
|
Effective concentration to inhibit hepatitis B virus cytopathicity in HepG2.2.15 cells was determined in vitro
|
Homo sapiens
|
200.0
nM
|
|
|
Compound concentration required to inhibit the viral cell proliferation by 50% against HBV
|
Hepatitis B virus
|
30.0
nM
|
|
|
Effective concentration against Hepatitis B virus in human hepatoblastoma cell line
|
Homo sapiens
|
70.0
nM
|
|
|
Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells)
|
Homo sapiens
|
10.0
nM
|
|
|
Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
|
Homo sapiens
|
38.0
nM
|
|
|
Effective concentration against Wild Type HIV-1 virus in human peripheral blood mononuclear cells
|
Human immunodeficiency virus 1
|
41.0
nM
|
|
|
Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes to 50% of untreated PHA stimulated control
|
Homo sapiens
|
50.0
ug.mL-1
|
|
|
Antiviral activity in MT-4 cells
|
Homo sapiens
|
370.0
nM
|
|
|
Antiviral activity in MT-4 cells expressed as IC50
|
Homo sapiens
|
370.0
nM
|
|
Antiviral activity in MT-4 cells expressed as IC50
|
Homo sapiens
|
610.0
nM
|
|
|
Compound was tested to inhibit HIV-1 replication in MT-4 cell lines
|
Homo sapiens
|
100.0
nM
|
|
|
In vitro concentration required to inhibit the cytopathicity of HIV-1 IIIB on MT-4 cell
|
Homo sapiens
|
400.0
nM
|
|
|
Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells
|
Homo sapiens
|
0.048
ug.mL-1
|
|
|
Antiviral activity against HIV-1 (strain RF) infected MT-4 cells
|
Human immunodeficiency virus 1
|
0.043
ug.mL-1
|
|
|
Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells
|
Homo sapiens
|
100.0
nM
|
|
|
Cytotoxicity against uninfected MT-4 cells
|
Homo sapiens
|
100.0
ug.mL-1
|
|
Cytotoxicity against uninfected MT-4 cells
|
Homo sapiens
|
100.0
ug.mL-1
|
|
|
Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro
|
None
|
500.0
nM
|
|
|
Antiviral activity in PBM cells
|
Homo sapiens
|
210.0
nM
|
|
|
Antiviral activity in PBM cells expressed as IC50
|
Homo sapiens
|
210.0
nM
|
|
Antiviral activity in PBM cells expressed as IC50
|
Homo sapiens
|
2.0
nM
|
|
|
Effective concentration to inhibit HIV-1 LAI cytopathicity in PBMC cells was determined in vitro
|
Homo sapiens
|
11.6
nM
|
|
|
In vitro concentration required to inhibit the HIV-1 LA1 replication on PBMCs cell (peripheral blood mononuclear cells)
|
Homo sapiens
|
10.0
nM
|
|
|
Activity against Lamivudine-resistant virus (HIV-1XXBRU) in human PBM cells, expressed as EC50
|
Homo sapiens
|
35.0
nM
|
|
|
Anti-HIV-1 activity against human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV
|
Human immunodeficiency virus
|
60.0
nM
|
|
Anti-HIV-1 activity against human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV
|
Human immunodeficiency virus
|
1.8
nM
|
|
Anti-HIV-1 activity against human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV
|
Human immunodeficiency virus
|
210.0
nM
|
|
|
Compound was tested for its anti-HIV activity against HIV-1 LAI in human peripheral blood mononuclear (PBM) cells
|
Homo sapiens
|
60.0
nM
|
|
|
Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV
|
Human immunodeficiency virus 1
|
210.0
nM
|
|
Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV
|
Human immunodeficiency virus 1
|
1.8
nM
|
|
|
In vitro anti-HIV activity in peripheral blood mononuclear cells.
|
None
|
70.0
nM
|
|
|
In vitro antiviral activity against HIV-1 Reverse transcriptase wild type
|
None
|
42.0
nM
|
|
|
Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes to 50% of untreated PHA Stimulated control
|
Homo sapiens
|
50.0
ug.mL-1
|
|
|
Effective concentration to inhibit 50 % of Epstein Barr virus replication in a cell culture model
|
epsteinBarr virus
|
400.0
nM
|
|
|
Effective concentrations at which 2-fold depression of extracellular virion DNA (HBV) was observed in 2.2.15 Cells
|
Hepatitis B virus
|
60.0
nM
|
|
|
Effective concentration required to inhibit hepatitis B virus replication in 2.2.15 cells in DNA hybridization assay
|
Hepatitis B virus
|
50.0
nM
|
|
|
In vitro effective concentration against Lamivudine resistant wild type HIV-1 in human peripheral blood mononuclear cells
|
Homo sapiens
|
27.0
nM
|
|
|
Effective concentrations at which 10-fold depression of intracellular intermediates of HBV DNA was observed in 2.2.15 Cells
|
Hepatitis B virus
|
230.0
nM
|
|
|
Inhibition of synthesis of extracellular virion DNA release in cultured human hepatoblastoma 2.2.15 cells
|
Hepatitis B virus
|
48.0
nM
|
|
|
Inhibition of synthesis of intracellular HBV DNA replicative intermediates in cultured human hepatoblastoma 2.2.15 cells
|
Hepatitis B virus
|
251.0
nM
|
|
|
Inhibition of duck HBV transfected in primary duck hepatocytes at 10 ug/mL
|
Duck hepatitis B virus
|
96.0
%
|
|
|
Inhibition of duck HBV transfected in primary duck hepatocytes
|
Duck hepatitis B virus
|
40.0
nM
|
|
|
Inhibition of wild type HBV transfected in human hepatoblastoma 2.2.15 cells at 10 ug/mL
|
Hepatitis B virus
|
88.0
%
|
|
|
Inhibition of HBV M204I mutant transfected in B1 cell line at 10 ug/mL
|
Hepatitis B virus
|
45.0
%
|
|
|
Inhibition of HBV L180M/ M204V mutant transfected in D88 cell line at 10 ug/mL
|
Hepatitis B virus
|
30.0
%
|
|
|
Antiviral activity against duck HBV in primary duck hepatocytes at 10 ug/mL
|
Duck hepatitis B virus
|
96.0
%
|
|
|
Antiviral activity against wild type HBV in human hepatoma 2.2.15 cells at 10 ug/mL
|
Hepatitis B virus
|
88.0
%
|
|
|
Antiviral activity against duck HBV in primary duck hepatocytes
|
Duck hepatitis B virus
|
40.0
nM
|
|
|
Antiviral activity against HBV L180M/M204V mutant transfected in D88 cell line at 10 ug/mL
|
Hepatitis B virus
|
30.0
%
|
|
|
Antiviral activity against HBV M204I mutant transfected in B1 cell line at 10 ug/mL
|
Hepatitis B virus
|
45.0
%
|
|
|
Inhibition of HBV DNA replication
|
Hepatitis B virus
|
380.0
nM
|
|
|
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
|
Hepatitis B virus
|
20.0
nM
|
|
|
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
|
Hepatitis B virus
|
20.0
nM
|
|
|
Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 100 uM by microplate alamar blue assay
|
Mycobacterium tuberculosis
|
0.0
%
|
|
|
Antimycobacterial activity against Mycobacterium bovis BCG at 100 uM by microplate alamar blue assay
|
Mycobacterium bovis BCG
|
0.0
%
|
|
|
Antimycobacterial activity against Mycobacterium avium ATCC 25291 at 100 uM by microplate alamar blue assay
|
Mycobacterium avium
|
0.0
%
|
|
|
Inhibition of cytoplasmic HBV DNA synthesis in HepG2.2.15 cells after 8 days
|
Hepatitis B virus
|
380.0
nM
|
|
|
Antiviral activity against wild type HBV genotype H assessed as inhibition of replication
|
Hepatitis B virus
|
640.0
nM
|
|
|
Antiviral activity against wild type HBV genotype E assessed as inhibition of replication
|
Hepatitis B virus
|
100.0
nM
|
|
|
Antiviral activity against HIV1 LAI in human PBM cells
|
Human immunodeficiency virus 1
|
26.0
nM
|
|
|
Antiviral activity against HIV1 with reverse transcriptase M184V mutation in human phytohemagglutininin-activated PBMC assessed as inhibition of viral replication at 60 uM
|
Human immunodeficiency virus 1
|
45.0
%
|
|
|
Antiviral activity against HIV1 with reverse transcriptase M184V mutation in human phytohemagglutininin-activated PBMC assessed as inhibition of viral replication at 200 uM
|
Human immunodeficiency virus 1
|
45.0
%
|
|
|
Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication
|
Hepatitis B virus
|
50.0
nM
|
|
|
Antiviral activity against HBV in adriamycin-resistant wild type HepW10 cells assessed as inhibition of viral DNA replication
|
Hepatitis B virus
|
100.0
nM
|
|
|
Antiviral activity against HBV in mouse ayw wild type HBV-Met cells assessed as inhibition of viral DNA replication
|
Hepatitis B virus
|
200.0
nM
|
|
|
Inhibition of HBV promoter in human HepG2(2.2.15) cells by luciferase reporter gene assay
|
Hepatitis B virus
|
80.0
nM
|
|
|
Antiviral activity against Hepatitis B virus cell culture assay
|
Hepatitis B virus
|
0.062
ug.mL-1
|
|
|
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
|
Human immunodeficiency virus 1
|
60.0
nM
|
|
|
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
|
Human immunodeficiency virus 1
|
60.0
nM
|
|
|
Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR
|
Hepatitis B virus
|
100.0
nM
|
|
|
Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
HBV genotype D
|
410.0
nM
|
|
|
Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
HBV genotype D
|
30.0
nM
|
|
|
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
HBV genotype D
|
460.0
nM
|
|
|
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
|
HBV genotype D
|
30.0
nM
|
|
|
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs
|
Hepatitis B virus
|
48.0
nM
|
|
|
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs
|
Hepatitis B virus
|
150.0
nM
|
|
|
Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
Hepatitis B virus
|
200.0
nM
|
|
|
Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
|
Hepatitis B virus
|
300.0
nM
|
|
|
Antiviral activity against wild type HIV1 NL4-3 produced from full length pR9deltaApa infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs
|
Human immunodeficiency virus 1
|
880.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as inhibition of HBsAg secretion at 200 ug/mL after 9 days by ELISA
|
Hepatitis B virus
|
28.6
%
|
|
|
Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as inhibition of HBeAg secretion at 200 ug/mL after 9 days by ELISA
|
Hepatitis B virus
|
34.8
%
|
|
|
Antiviral activity against Hepatitis B virus infected human HepG2.2.15 cells assessed as HBsAg secretion at 200 ug/kg after 9 days by ELISA
|
Hepatitis B virus
|
28.6
%
|
|
|
Antiviral activity against Hepatitis B virus infected human HepG2.2.15 cells assessed as HBeAg secretion at 200 ug/kg after 9 days by ELISA
|
Hepatitis B virus
|
34.5
%
|
|
|
Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 days by ELISA
|
Human immunodeficiency virus 1
|
200.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication
|
Hepatitis B virus
|
220.0
nM
|
|
|
Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
Hepatitis B virus
|
200.0
nM
|
|
|
Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
|
Hepatitis B virus
|
200.0
nM
|
|
|
Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay
|
Hepatitis B virus
|
14.8
ug.mL-1
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis
|
Hepatitis B virus
|
160.0
nM
|
|
|
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication
|
Duck hepatitis B virus
|
44.0
nM
|
|
|
Antiviral activity against HBV assessed as inhibition of viral DNA replication
|
Hepatitis B virus
|
220.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
Human immunodeficiency virus 1
|
202.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
Human immunodeficiency virus 1
|
105.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
Human immunodeficiency virus 1
|
183.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
Human immunodeficiency virus 1
|
47.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
Human immunodeficiency virus 1
|
182.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
Human immunodeficiency virus 1
|
171.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
Human immunodeficiency virus 1
|
850.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
Human immunodeficiency virus 1
|
71.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
Human immunodeficiency virus 1
|
81.0
nM
|
|
|
Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
Human immunodeficiency virus 1
|
63.0
nM
|
|
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
Human immunodeficiency virus 1
|
86.0
nM
|
|
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
Human immunodeficiency virus 1
|
372.0
nM
|
|
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
Human immunodeficiency virus 1
|
462.0
nM
|
|
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
Human immunodeficiency virus 1
|
667.0
nM
|
|
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
Human immunodeficiency virus 1
|
219.0
nM
|
|
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
Human immunodeficiency virus 1
|
554.0
nM
|
|
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
Human immunodeficiency virus 1
|
969.0
nM
|
|
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
Human immunodeficiency virus 1
|
927.0
nM
|
|
|
Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
|
Antiviral activity against HBV infected in duck primary hepatocytes at 10 ug/ml
|
Hepatitis B virus
|
96.0
%
|
|
|
Antiviral activity against HBV infected in duck primary hepatocytes
|
Hepatitis B virus
|
0.05
ug.mL-1
|
|
|
Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml
|
Hepatitis B virus
|
88.0
%
|
|
|
Antiviral activity against HBV infected in human 2.2.15 cell
|
Hepatitis B virus
|
0.2
ug.mL-1
|
|
|
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication at 0.5 to 1 ug/ml after 2 days relative to control
|
Duck hepatitis B virus
|
96.0
%
|
|
|
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days
|
Duck hepatitis B virus
|
0.05
ug.mL-1
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication at 0.5 to 1 ug/ml after 2 days relative to control
|
Hepatitis B virus
|
88.0
%
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days
|
Hepatitis B virus
|
0.2
ug.mL-1
|
|
|
PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Confirmation HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1). (Class of assay: confirmatory) [Related pubchem assays: 2118 (Project Summary), 2098 (Primary HTS)]
|
Mus musculus
|
287.0
nM
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA
|
Hepatitis B virus
|
4.51
ug.mL-1
|
|
|
Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
Hepatitis B virus
|
200.0
nM
|
|
|
Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
|
Hepatitis B virus
|
300.0
nM
|
|
|
Antiviral activity against wild-type HIV1 pNL4-3 infected in TZM-bl cells by luciferase assay
|
Human immunodeficiency virus 1
|
650.0
nM
|
|
|
Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
470.0
nM
|
|
|
Antiviral activity against wild type HBV infected in human Huh7.5 cells assessed as reduction of viral replication at 0.16 ug/ml after 36 hrs
|
Hepatitis B virus
|
64.0
%
|
|
|
Antiviral activity against lamivudine-resistant HBV infected in human Huh7.5 cells assessed as reduction of viral replication at 0.16 ug/ml after 36 hrs
|
Hepatitis B virus
|
28.0
%
|
|
|
Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
780.0
nM
|
|
|
Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
600.0
nM
|
|
|
Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
30.0
nM
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 10 uM after 14 days by real-time PCR
|
Homo sapiens
|
1.0
%
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 100 uM after 14 days by real-time PCR
|
Homo sapiens
|
99.96
%
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 10 uM after 14 days by real-time PCR
|
Homo sapiens
|
1.0
%
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 100 uM after 14 days by real-time PCR
|
Homo sapiens
|
94.3
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting
|
Hepatitis B virus
|
60.0
nM
|
|
|
Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting
|
Hepatitis B virus
|
100.0
nM
|
|
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
|
Human immunodeficiency virus 1
|
800.0
nM
|
|
|
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
|
Human immunodeficiency virus 1
|
800.0
nM
|
|
|
Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression at 22.93 ug/ml after 3 weeks post infection by quantitative real time RT-PCR
|
Human T-lymphotropic virus 1
|
100.0
%
|
|
|
Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression at 0.23 ug/ml after 5 days post infection by quantitative real time RT-PCR
|
Human immunodeficiency virus 1
|
100.0
%
|
|
|
Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression after 3 weeks post infection by quantitative real time RT-PCR
|
Human T-lymphotropic virus 1
|
14.24
ug.mL-1
|
|
|
Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression after 5 days post infection by quantitative real time RT-PCR
|
Human immunodeficiency virus 1
|
0.19
ug.mL-1
|
|
|
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
|
Human immunodeficiency virus 1
|
800.0
nM
|
|
|
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
|
Human immunodeficiency virus 1
|
800.0
nM
|
|
|
Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication at 10 nM by p24 HIV antigen capture assay relative to control
|
Human immunodeficiency virus 1
|
37.0
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis
|
Hepatitis B virus
|
330.0
nM
|
|
|
Antiviral activity against HIV1 LAV1 infected in phytohemagglutininin-stimulated human PBMC assessed as RT level after 6 days by microdilution plate assay
|
Human immunodeficiency virus 1
|
67.0
nM
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepAD38 assessed as reduction of viral DNA level on day 7 by quantitative-PCR assay analysis
|
Hepatitis B virus
|
60.0
nM
|
|
|
Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method
|
Hepatitis B virus
|
200.0
nM
|
|
|
Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method
|
Hepatitis B virus
|
200.0
nM
|
|
|
Antiviral activity against wild type HIV1 clade B 94US3393IN clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay
|
Human immunodeficiency virus 1
|
87.3
nM
|
|
|
Antiviral activity against wild type HIV1 clade C 98USMSC5016 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay
|
Human immunodeficiency virus 1
|
21.8
nM
|
|
|
Antiviral activity against NNRTI-resistant HIV1 clade B A-17 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay
|
Human immunodeficiency virus 1
|
92.1
nM
|
|
|
Antiviral activity against HIV-1 subtype B US/92/727 infected in PBMC assessed as inhibition of viral replication after 7 days by XTT assay
|
Human immunodeficiency virus 1
|
90.0
nM
|
|
|
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
|
Human immunodeficiency virus 1
|
200.0
nM
|
|
|
Antiviral activity against HIV1 94US3393IN clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation counting
|
Human immunodeficiency virus 1
|
87.3
nM
|
|
|
Antiviral activity against HIV1 98USMSC5016 clade C clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation counting
|
Human immunodeficiency virus 1
|
21.8
nM
|
|
|
Antiviral activity against NNTRI-resistant HIV1 A-17 clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation counting
|
Human immunodeficiency virus 1
|
92.1
nM
|
|
|
Antiviral activity against NRTI-resistant HIV1 71361-1 clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation counting
|
Human immunodeficiency virus 1
|
812.0
nM
|
|
|
Antiviral activity against Hepatitis B virus infected in HepG2(2.2.15) cells assessed as reduction in HBsAg level at 20 uM after 9 days by ELISA
|
Hepatitis B virus
|
45.0
%
|
|
|
Antiviral activity against Duck hepatitis B virus infected in pekin duck primary hepatocytes assessed as inhibition of viral replication at 0.5 to 1 ug/mL
|
Duck hepatitis B virus
|
96.0
%
|
|
|
Antiviral activity against Duck hepatitis B virus infected in pekin duck primary hepatocytes assessed as inhibition of viral replication
|
Duck hepatitis B virus
|
0.05
ug.mL-1
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication at 0.5 to 1 ug/mL
|
Hepatitis B virus
|
88.0
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication
|
Hepatitis B virus
|
0.2
ug.mL-1
|
|
|
Antiviral activity against wild type Hepatitis B virus infected in human HuH7 cells
|
Hepatitis B virus
|
56.0
nM
|
|
|
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
|
Human immunodeficiency virus type 2 (ISOLATE ROD)
|
180.0
nM
|
|
|
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
|
Human immunodeficiency virus 1
|
99.0
nM
|
|
|
Antiviral activity against Hepatitis B virus assessed as inhibition of Hepatitis B virus DNA replication
|
Hepatitis B virus
|
260.0
nM
|
|
|
Antiviral activity against Hepatitis B virus assessed as inhibition of viral infection by DNA virion assay
|
Hepatitis B virus
|
35.0
nM
|
|
|
Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
890.0
nM
|
|
|
Antiviral activity against hepatitis B viral in human HepG2(2.2.15) cells assessed as decrease in surface antigen HBsAg secretion at 25 ug/ml after 7 days
|
Hepatitis B virus
|
10.0
%
|
|
|
Antiviral activity against hepatitis B viral in human HepG2(2.2.15) cells assessed as decrease in surface antigen HBeAg secretion at 25 ug/ml after 7 days
|
Hepatitis B virus
|
46.0
%
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA
|
Hepatitis B virus
|
49.13
ug.mL-1
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication
|
Hepatitis B virus
|
41.0
ug.mL-1
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 300 uM after 3 days by ELISA
|
Hepatitis B virus
|
37.26
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 150 uM after 3 days by ELISA
|
Hepatitis B virus
|
28.56
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 75 uM after 3 days by ELISA
|
Hepatitis B virus
|
21.98
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 37.5 uM after 3 days by ELISA
|
Hepatitis B virus
|
11.59
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 300 uM after 6 days by ELISA
|
Hepatitis B virus
|
43.59
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 150 uM after 6 days by ELISA
|
Hepatitis B virus
|
30.7
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 75 uM after 6 days by ELISA
|
Hepatitis B virus
|
24.15
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 37.5 uM after 6 days by ELISA
|
Hepatitis B virus
|
7.98
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 300 uM after 9 days by ELISA
|
Hepatitis B virus
|
60.36
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 150 uM after 9 days by ELISA
|
Hepatitis B virus
|
55.86
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 75 uM after 9 days by ELISA
|
Hepatitis B virus
|
33.11
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 37.5 uM after 9 days by ELISA
|
Hepatitis B virus
|
25.23
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 300 uM after 9 days (Rvb = 100%)
|
Hepatitis B virus
|
75.19
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 150 uM after 9 days (Rvb = 100%)
|
Hepatitis B virus
|
82.39
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 75 uM after 9 days (Rvb = 100%)
|
Hepatitis B virus
|
95.86
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 37.5 uM after 9 days (Rvb = 100%)
|
Hepatitis B virus
|
118.45
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 3 days by ELISA
|
Hepatitis B virus
|
30.87
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 150 uM after 3 days by ELISA
|
Hepatitis B virus
|
23.93
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 75 uM after 3 days by ELISA
|
Hepatitis B virus
|
15.09
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 37.5 uM after 3 days by ELISA
|
Hepatitis B virus
|
10.13
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 6 days by ELISA
|
Hepatitis B virus
|
39.92
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 150 uM after 6 days by ELISA
|
Hepatitis B virus
|
31.12
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 75 uM after 6 days by ELISA
|
Hepatitis B virus
|
22.05
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 37.5 uM after 6 days by ELISA
|
Hepatitis B virus
|
12.78
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 9 days by ELISA
|
Hepatitis B virus
|
4.0
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 150 uM after 9 days by ELISA
|
Hepatitis B virus
|
45.36
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 75 uM after 9 days by ELISA
|
Hepatitis B virus
|
34.17
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 37.5 uM after 9 days by ELISA
|
Hepatitis B virus
|
18.39
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 300 uM after 3 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
59.45
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 150 uM after 3 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
46.61
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 75 uM after 3 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
45.96
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 37.5 uM after 3 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
39.97
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 300 uM after 6 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
71.59
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 150 uM after 6 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
66.83
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 75 uM after 6 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
58.89
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 37.5 uM after 6 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
38.57
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 300 uM after 9 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
86.39
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 150 uM after 9 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
81.64
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 75 uM after 9 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
76.68
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 37.5 uM after 9 days by real-time fluorescence quantitative PCR analysis
|
Hepatitis B virus
|
69.42
%
|
|
|
Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 20 mg/kg/day, po treatment initiated at day 5 after infection relative to control
|
Duck hepatitis B virus
|
88.6
%
|
|
|
Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 20 mg/kg/day, po treatment initiated at day 10 after infection relative to control
|
Duck hepatitis B virus
|
82.2
%
|
|
|
Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 20 mg/kg/day, po measured after 3 days of treatment withdrawal
|
Duck hepatitis B virus
|
79.3
%
|
|
|
Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in liver at 20 mg/kg/day, po treatment initiated at day 5 after infection relative to control
|
Duck hepatitis B virus
|
52.7
%
|
|
|
Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in liver at 20 mg/kg/day, po treatment initiated at day 10 after infection relative to control
|
Duck hepatitis B virus
|
84.0
%
|
|
|
Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in liver at 20 mg/kg/day, po measured after 3 days of treatment withdrawal
|
Duck hepatitis B virus
|
76.2
%
|
|
|
Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay
|
Hepatitis B virus
|
39.0
nM
|
|
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
0.58
ug.mL-1
|
|
|
Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy number after 6 days by real-time qPCR method
|
Hepatitis B virus
|
10.0
nM
|
|
|
Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy number after 6 days by real-time qPCR method
|
Hepatitis B virus
|
10.0
nM
|
|
|
Antiviral activity against HBV infected in human HepAD38 cells assessed as inhibition of DNA replication after 5 days by RT-PCR method
|
Hepatitis B virus
|
40.0
nM
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels
|
Homo sapiens
|
16.0
%
|
|
|
Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels
|
Homo sapiens
|
38.0
%
|
|
|
Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy number after 6 days by real-time qPCR method
|
Hepatitis B virus
|
20.0
nM
|
|
|
Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy number after 6 days byr by real-time qPCR assay
|
Hepatitis B virus
|
8.87
nM
|
|
|
Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
100.0
nM
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 20 uM after 8 days by real time fluorescent PCR method relative to control
|
Hepatitis B virus
|
81.9
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 4 uM after 8 days by real time fluorescent PCR method relative to control
|
Hepatitis B virus
|
80.8
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 0.8 uM after 8 days by real time fluorescent PCR method relative to control
|
Hepatitis B virus
|
56.2
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 0.16 uM after 8 days by real time fluorescent PCR method relative to control
|
Hepatitis B virus
|
37.0
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication after 8 days by real time fluorescent PCR method
|
Hepatitis B virus
|
500.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 20 uM after 6 days by RT-PCR method relative to control
|
Hepatitis B virus
|
92.66
%
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 6 days by RT-PCR method
|
Hepatitis B virus
|
100.0
nM
|
|
|
Antiviral activity against lamivudine/entecavir resistant HBV harboring reverse transcriptase L180M/M204V/T184L mutant infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 100 uM after 72 hrs by RT-PCR method relative to control
|
Hepatitis B virus
|
19.37
%
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 100 uM after 72 hrs by RT-PCR method relative to control
|
Hepatitis B virus
|
94.28
%
|
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of intracellular viral pregenomic RNA expression at 1 uM after 6 days by TRIzol reagent based RT-PCR method relative to control
|
Hepatitis B virus
|
0.81
%
|
|
|
Antiviral activity against lamivudine-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis
|
Hepatitis B virus
|
237.0
nM
|
|
|
Antiviral activity against lamivudine-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis
|
Hepatitis B virus
|
55.0
nM
|
|
|
Antiviral activity against hepatitis B virus infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis
|
Hepatitis B virus
|
100.0
nM
|
|
|
Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in cccDNA formation by measuring reduction in HBe antigen secretion at 10 uM after 14 days by ELISA relative to control
|
Hepatitis B virus
|
1.0
%
|
|
|
Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in viral replication by RT-PCR method
|
Hepatitis B virus
|
40.0
nM
|
|
|
Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in extracellular viral DNA level by RT-PCR method
|
Hepatitis B virus
|
40.0
nM
|
|
|
Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in intracellular viral DNA level by RT-PCR method
|
Hepatitis B virus
|
10.0
nM
|
|
|
Antiviral activity against HIV1 virions derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed virions followed by incubation with target cells for 24 hrs by luciferase reporter gene assay based defective HIV1 pseudoviral assay
|
Human immunodeficiency virus 1
|
510.0
nM
|
|
|
Antiviral activity against HIV1 infected in human PBMC incubated for 24 hrs in presence of 10% NHS by GFP based single cycle HIV replication assay
|
Human immunodeficiency virus 1
|
171.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 1 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control
|
Hepatitis B virus
|
31.5
%
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 1 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control
|
Hepatitis B virus
|
37.5
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 20 uM after 9 days by ELISA relative to control
|
Hepatitis B virus
|
22.1
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 20 uM after 9 days by ELISA relative to control
|
Hepatitis B virus
|
47.7
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA level at 20 uM measured on day 9 by FQ-PCR analysis
|
Hepatitis B virus
|
85.7
%
|
|
|
Antiviral activity against Hepatitis B virus harboring rtV173L/L180M/M204V mutant infected in HepGRL1 cells assessed as inhibition of intracellular HBV DNA level at 20 uM measured on day 9 by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
12.9
%
|
|
|
Antiviral activity against Hepatitis B virus harboring rtV173L/L180M/M204V mutant infected in HepGRL1 cells assessed as inhibition of intracellular HBV DNA level at 20 uM measured on day 6 by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
10.8
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as intracellular HBV DNA levels at 20 uM measured on day 6 by FQ-PCR analysis
|
Hepatitis B virus
|
75.4
%
|
|
|
Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in serum at 10 mg/kg, po administered once daily measured on day 10 by SYBR Green I dye-based FQ-PCR analysis relative to control
|
Duck hepatitis B virus
|
65.2
%
|
|
|
Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in serum at 10 mg/kg, po administered once daily measured on day 15 by SYBR Green I dye-based FQ-PCR analysis relative to control
|
Duck hepatitis B virus
|
85.7
%
|
|
|
Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in liver at 10 mg/kg, po administered once daily measured on day 10 by SYBR Green I dye-based FQ-PCR analysis relative to control
|
Duck hepatitis B virus
|
57.1
%
|
|
|
Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in liver at 10 mg/kg, po administered once daily measured on day 15 by SYBR Green I dye-based FQ-PCR analysis relative to control
|
Duck hepatitis B virus
|
75.6
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in extracellular viral DNA levels after 6 days by qPCR/TaqMan assay
|
Hepatitis B virus
|
25.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
9.88
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
8.04
%
|
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
20.65
%
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
10.87
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
11.08
%
|
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
2.4
%
|
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-7.82
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-1.99
%
|
|
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytial cell formation incubated for 72 hrs
|
Human immunodeficiency virus 1
|
300.0
nM
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days and measured on day 9 by ELISA relative to control
|
Hepatitis B virus
|
39.6
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days and measured on day 9 by ELISA relative to control
|
Hepatitis B virus
|
42.4
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
47.4
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
69.7
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 9 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
77.9
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
32.7
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
54.1
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 9 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
78.6
%
|
|
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
6.3
%
|
|
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
7.9
%
|
|
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 9 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
11.2
%
|
|
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
4.1
%
|
|
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
8.4
%
|
|
|
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 9 days measured post-last dose by FQ-PCR analysis relative to control
|
Hepatitis B virus
|
19.3
%
|
|
|
Inhibition of capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level supplemented with fresh medium containing compound every 2 days and measured after 6 days by RT-PCR analysis relative to control
|
Hepatitis B virus
|
94.31
%
|
|
|
Inhibition of capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 4 uM supplemented with fresh medium containing compound every 2 days and measured after 6 days by RT-PCR analysis
|
Hepatitis B virus
|
100.0
nM
|
|
|
Inhibition of capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 100 uM measured after 72 hrs by PCR analysis relative to control
|
Hepatitis B virus
|
17.73
%
|
|
|
Inhibition of capsid protein in wild type Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 100 uM measured after 72 hrs by PCR analysis relative to control
|
Hepatitis B virus
|
90.67
%
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level at 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
|
Homo sapiens
|
10.0
%
|
|
|
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level at 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
|
Homo sapiens
|
10.0
%
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15.7 cells assessed as inhibition of viral DNA level after 9 days by real time PCR method
|
Hepatitis B virus
|
30.0
nM
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
22.44
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
12.92
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.03
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.04
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.04
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.03
%
|
|
|
Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis
|
Hepatitis B virus
|
70.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis
|
Hepatitis B virus
|
3.8
nM
|
|
|
Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay
|
Human immunodeficiency virus 1
|
300.0
nM
|
|
|
Antiviral activity against wild type HIV-1 strain 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
Human immunodeficiency virus 1
|
18.0
nM
|
|
|
Antiviral activity against HIV-1 K103N mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
Human immunodeficiency virus 1
|
19.0
nM
|
|
|
Antiviral activity against HIV-1 Y181C mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
Human immunodeficiency virus 1
|
12.0
nM
|
|
|
Antiviral activity against HIV-1 E138K mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
Human immunodeficiency virus 1
|
19.0
nM
|
|
|
Antiviral activity against HIV-1 RES056 mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
Human immunodeficiency virus 1
|
28.0
nM
|
|
|
Antiviral activity against HIV-2 ROD strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
Human immunodeficiency virus type 1
|
21.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as decrease in extracellular viral DNA level at 0.8 uM measured after incubation of 6 days by RT-PCR analysis
|
Hepatitis B virus
|
86.23
%
|
|
|
Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as decrease in extracellular viral DNA level measured after incubation of 6 days by RT-PCR analysis
|
Hepatitis B virus
|
31.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as inhibition of pregenomic RNA expression at 1 uM measured after incubation of 6 by RT-PCR analysis relative to control
|
Hepatitis B virus
|
63.13
%
|
|
|
Antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication at 100 uM measured after incubation of 72 hrs by RT-PCR analysis relative to control
|
Hepatitis B virus
|
90.01
%
|
|
|
Antiviral activity against lamivudine/entecavir-resistant HBV rtL180M/rtM204V/rtT184L mutant infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication at 100 uM measured after incubation of 72 hrs by RT-PCR analysis relative to control
|
Hepatitis B virus
|
18.58
%
|
|
|
Antiviral activity against Hepatitis B virus infected in human HePAD38 cells assessed as reduction in viral DNA replication incubated for 7 days by RT-PCR analysis
|
Hepatitis B virus
|
410.0
nM
|
|
|
Antiviral activity against HBV infected in human HepAD38 cells assessed as inhibition of viral DNA at 10 uM incubated for 4 days by SYBR green dye based RT-PCR analysis relative to control
|
Hepatitis B virus
|
70.0
%
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in intracellular viral DNA level at 100 uM incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by fluorogenic probe based RT-qPCR analysis relative to control
|
Hepatitis B virus
|
87.9
%
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in intracellular viral DNA level incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by fluorogenic probe based RT-qPCR analysis
|
Hepatitis B virus
|
600.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 0.8 uM supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis relative to control
|
Hepatitis B virus
|
84.42
%
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis
|
Hepatitis B virus
|
100.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg production supplemented with fresh medium containing compound every 3 days for 6 days by EIA relative to control
|
Hepatitis B virus
|
9.09
%
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 100 uM supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis relative to control
|
Hepatitis B virus
|
90.0
%
|
|
|
Antiviral activity against lamivudine and entecavir-resistant HBV harboring rtL180 M/rtM204V/rtT184L mutant infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 100 uM supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis relative to control
|
Hepatitis B virus
|
15.69
%
|
|
|
Antiviral activity against HIV13B infected in human H9 cells assessed as p24 level incubated for 7 days by ELISA
|
Human immunodeficiency virus 1
|
210.0
nM
|
|
|
Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication incubated for 3 days by strand preferential qPCR analysis
|
Hepatitis B virus
|
370.0
nM
|
|
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral replication incubated for 8 days by southern blotting analysis
|
Hepatitis B virus
|
325.0
nM
|
|
